HUMAW
Humacyte IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-3.16
Beta
2.52
52W High
$0.60
52W Low
$0.00
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Humacyte Inc
Humacyte Inc. is a cutting-edge biotechnology company pioneering the development and commercialization of universally implantable human tissues, with its flagship human acellular vessel (HAV) technology. The firm is revolutionizing vascular and regenerative medicine by utilizing advanced manufacturing processes and comprehensive clinical trial advancements to tackle critical healthcare issues. With a strategic emphasis on enhancing patient outcomes through its innovative tissue-based solutions, Humacyte is well-positioned for impactful collaborations and substantial growth in the regenerative medicine landscape. By addressing urgent medical needs, the company aims to make a transformative contribution to the future of healthcare.
Fundamentals
| Revenue (TTM) | $2.02M |
| Gross Profit (TTM) | $-81.72M |
| EBITDA | $-105.19M |
| Operating Margin | -5704.00% |
| Return on Equity | -409.50% |
| Return on Assets | -51.50% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.05 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -4.30% |
| Shares Outstanding | 0 |
| Float | $196.13M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Data last updated: 7/9/2026